---
figid: PMC5418249__jtd-09-04-E384-f1
figlink: /pmc/articles/PMC5418249/figure/f1/
number: Figure 1
caption: PD-1:PD-L1 mechanisms between T-cells and tumor cells. (A) Loss of phosphatase
  and tensin homolog (PTEN) in tumor cells induces the Phosphoinositol-3-kinase (PI3K)—Akt
  pathway with consecutive overexpression of PD-L1 (); (B) once PD-L1 binds to PD-1,
  the resulting inhibition influences tumor surveillance such as Fas-mediated apoptosis
  (). By co-activation of PD-1 concomitant to TCR in T-cells, the phosphorylation
  of the SHP-2 domain results in a down-regulation of the PI3K-Akt pathway. This step
  alters the mTOR complex, which regulates T cellular differentiation (); (C) upon
  immune checkpoint inhibition, either with PD-L1-mAb (Atezolizumab) or PD-1-mAbs
  (Pembrolizumab and Nivolumab), T-cell differentiation is switched to CD8+ T effector
  (T eff) or T memory (T mem) cells, inducing apoptosis by completing the major histocompatibility
  complex (MHC) of the tumor cells ().
pmcid: PMC5418249
papertitle: PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell
  lung cancer patients.
reftext: Arik Bernard Schulze, et al. J Thorac Dis. 2017 Apr;9(4):E384-E386.
pmc_ranked_result_index: '156112'
pathway_score: 0.9653818
filename: jtd-09-04-E384-f1.jpg
figtitle: PD-1:PD-L1 mechanisms between T-cells and tumor cells
year: '2017'
organisms: Homo sapiens
ndex: 49565d8b-dea8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5418249__jtd-09-04-E384-f1.html
  '@type': Dataset
  description: PD-1:PD-L1 mechanisms between T-cells and tumor cells. (A) Loss of
    phosphatase and tensin homolog (PTEN) in tumor cells induces the Phosphoinositol-3-kinase
    (PI3K)—Akt pathway with consecutive overexpression of PD-L1 (); (B) once PD-L1
    binds to PD-1, the resulting inhibition influences tumor surveillance such as
    Fas-mediated apoptosis (). By co-activation of PD-1 concomitant to TCR in T-cells,
    the phosphorylation of the SHP-2 domain results in a down-regulation of the PI3K-Akt
    pathway. This step alters the mTOR complex, which regulates T cellular differentiation
    (); (C) upon immune checkpoint inhibition, either with PD-L1-mAb (Atezolizumab)
    or PD-1-mAbs (Pembrolizumab and Nivolumab), T-cell differentiation is switched
    to CD8+ T effector (T eff) or T memory (T mem) cells, inducing apoptosis by completing
    the major histocompatibility complex (MHC) of the tumor cells ().
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT1
  - CD8B
  - MERTK
  - APC
  - CD8A
  - PIK3R5
  - PIK3R4
  - AKT3
  - AKT2
  - PIK3CB
  - PIK3CD
  - PIK3R3
  - TRG
  - MTOR
  - PIK3R6
  - ZAP70
  - PDCD1
  - PIK3CA
  - PTPN11
  - TRA
  - PTEN
  - PIK3CG
  - CD274
  - TRD
  - TRB
  - Cancer
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Akt1
  symbol: AKT1
  source: hgnc_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: mer
  symbol: mer
  source: hgnc_alias_symbol
  hgnc_symbol: MERTK
  entrez: '10461'
- word: APC
  symbol: APC
  source: hgnc_symbol
  hgnc_symbol: APC
  entrez: '324'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: ZAP70
  symbol: ZAP70
  source: hgnc_symbol
  hgnc_symbol: ZAP70
  entrez: '7535'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: SHP-2
  symbol: SHP-2
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN11
  entrez: '5781'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
